Eli Lilly Approved Obesity Drug for Mystery 79-Year-Old Patient
Eli Lilly secured FDA approval for its obesity drug Zepbound for a second new use—obstructive sleep apnea—after a 79-year-old patient in a clinical trial died. The company disclosed the death to the FDA but did not publicly name the patient, raising scrutiny around transparency and the drug's safety profile.
Background
- The article reports that Eli Lilly obtained FDA approval for its obesity drug Zepbound (tirzepatide) to treat a specific 79-year-old patient whose identity was redacted — fueling speculation that the patient is Donald Trump, who is 79 and reportedly seeking weight-loss medications.
- Zepbound is a GLP-1 receptor agonist (same class as Ozempic/Wegovy), originally approved for type 2 diabetes (as Mounjaro) and later for weight loss. The FDA allows "compassionate use" / expanded access for individual patients who don't qualify under standard approvals.
- Trump has publicly asked about weight-loss drugs, and his physician recently confirmed he started taking a GLP-1 medication. The timing of Eli Lilly's patient-specific approval aligns with that news, prompting widespread speculation despite the redacted name.